Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients

Inclusion Criteria: * Signed and dated informed consent, * Male or female aged \> 18 years old, * Both eyes with open angle glaucoma or ocular hypertension already treated and controlled by Xalacom® or generics (fixed combination Latanoprost 0.005% + Timolol 0.5% preserved eye drops) since at least 2 months. * IOP ≤ 18 mmHg in both eyes * History of IOP insufficiently controlled with first-line monotherapy based on the investigator judgement (e.g. non reaching the target IOP) * History of an add-on IOP reduction with Xalacom® or generics (fixed combination Latanoprost 0.005% + Timolol 0.5% preserved eye drops) in comparison with first-line treatment * Corneal thickness ≥ 500 μm and ≤ 600 μm in both eyes. Exclusion Criteria: * Ophthalmic exclusion criteria (in either eye) * Fundoscopy, VF not performed or not available within the 6 months before inclusion visit. * Significant worsening according to the two last VF (minimum 6 months between these 2 VF) * Advanced stage of glaucoma: * Best far corrected visual acuity ≤ 1/10. * History of trauma, infection, clinically significant inflammation within the 3 months before inclusion visit. * Ongoing or known history of ocular seasonal and perennial allergy (SAC, PAC) and/or uveitis and/or viral infection. * Presence of at least one severe objective sign among the following: * Hyperaemia (Grade 5) * Superficial punctate keratitis (Grade 3) * Blepharitis (Grade 3) * Severe dry eye (defined by severe epithelial erosions of the cornea and/or use of dry eye medication with a frequency exceeding 8 instillations / day). * Corneal ulceration. * Palpebral abnormalities not related to medical treatment study and incompatible with a good evaluation. * History of corneal refractive surgery. * Any abnormality preventing accurate assessment e.g. reliable tonometry measurement, visual field examination. Systemic/non ophthalmic exclusion criteria * Non-controlled diabetic patient. * Reactive airway disease including bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease. * Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block not controlled with pace-maker, overt cardiac failure, cardiogenic shock. * Heart rate \<50 bpm, systolic arterial blood pressure≤ 90 mm Hg * Known or suspected hypersensitivity to one of the components of the study product. * Any medical or surgical history, disorder or disease such as acute or chronic severe organic disease: hepatic, endocrine, neoplastic, haematological; immunosuppressive, infectious diseases, severe psychiatric illness, relevant cardiovascular abnormalities, etc… and/or any complicating factor or structural abnormality, judged by the investigator to be incompatible with the study. Specific exclusion criteria for women * Pregnancy, lactation. * Childbearing potential woman who is not using a reliable method of contraception Exclusion criteria related to general conditions * Inability of patient to understand the study procedures and thus inability to give informed consent. * Non-compliant patient * Participation in another clinical study with investigational drug within the last 3 months. * Already included once in this study. * Patients being institutionalised because of legal or regulatory order, inmates of psychiatric wards, prison or state institutions, and employees of the study sites or of the Sponsor's company. * Ward of court. * Patient not covered by government health care scheme in the country (if applicable).